| pubmed-article:1457270 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1457270 | lifeskim:mentions | umls-concept:C0042036 | lld:lifeskim |
| pubmed-article:1457270 | lifeskim:mentions | umls-concept:C1524119 | lld:lifeskim |
| pubmed-article:1457270 | lifeskim:mentions | umls-concept:C0000970 | lld:lifeskim |
| pubmed-article:1457270 | lifeskim:mentions | umls-concept:C0311400 | lld:lifeskim |
| pubmed-article:1457270 | lifeskim:mentions | umls-concept:C0456603 | lld:lifeskim |
| pubmed-article:1457270 | lifeskim:mentions | umls-concept:C2826285 | lld:lifeskim |
| pubmed-article:1457270 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:1457270 | pubmed:dateCreated | 1993-1-12 | lld:pubmed |
| pubmed-article:1457270 | pubmed:abstractText | The effects of high and low urine flow rates on the urinary metabolic ratios for paracetamol glucuronidation, sulphation and oxidation were determined at steady-state in seven healthy young adult volunteers. Metabolic partial clearances were unaffected by urine flow rate, but individual paracetamol metabolic ratios varied 2.5- to 3.2-fold over a 7.4-fold range of urine flow rates (0.81-6.00 ml min-1). The change in metabolic ratios was due entirely to a 2.5-fold change in renal clearance of unchanged paracetamol. These data emphasise the limitations of the metabolic ratio as a measure of intrinsic clearance for compounds which undergo some degree of tubular reabsorption. | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1457270 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1457270 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1457270 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1457270 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1457270 | pubmed:issn | 0306-5251 | lld:pubmed |
| pubmed-article:1457270 | pubmed:author | pubmed-author:TonkinA LAL | lld:pubmed |
| pubmed-article:1457270 | pubmed:author | pubmed-author:BirkettD JDJ | lld:pubmed |
| pubmed-article:1457270 | pubmed:author | pubmed-author:MinersJ OJO | lld:pubmed |
| pubmed-article:1457270 | pubmed:author | pubmed-author:OsborneN JNJ | lld:pubmed |
| pubmed-article:1457270 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1457270 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:1457270 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1457270 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1457270 | pubmed:pagination | 359-62 | lld:pubmed |
| pubmed-article:1457270 | pubmed:dateRevised | 2010-9-7 | lld:pubmed |
| pubmed-article:1457270 | pubmed:meshHeading | pubmed-meshheading:1457270-... | lld:pubmed |
| pubmed-article:1457270 | pubmed:meshHeading | pubmed-meshheading:1457270-... | lld:pubmed |
| pubmed-article:1457270 | pubmed:meshHeading | pubmed-meshheading:1457270-... | lld:pubmed |
| pubmed-article:1457270 | pubmed:meshHeading | pubmed-meshheading:1457270-... | lld:pubmed |
| pubmed-article:1457270 | pubmed:meshHeading | pubmed-meshheading:1457270-... | lld:pubmed |
| pubmed-article:1457270 | pubmed:meshHeading | pubmed-meshheading:1457270-... | lld:pubmed |
| pubmed-article:1457270 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1457270 | pubmed:articleTitle | Perturbation of paracetamol urinary metabolic ratios by urine flow rate. | lld:pubmed |
| pubmed-article:1457270 | pubmed:affiliation | Department of Clinical Pharmacology, Flinders Medical Centre, Adelaide, Australia. | lld:pubmed |
| pubmed-article:1457270 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1457270 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
